Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Am J Obstet Gynecol. 2019 Nov 6;222(5):478.e1–478.e17. doi: 10.1016/j.ajog.2019.10.103

Table 2.

Analytic baseline characteristics of study sample

Study Overall ALSWH NSHD NCDS SWAN WHITEHALL SMWHS HOW JMWHS
n 21,460 10,323 1,068 3,983 2,345 2,041 189 768 743
Birth year
 <1940 3.8 N/A N/A N/A N/A 39.5 0.5 N/A N/A
 1940–1949 54.9 74.3 100 N/A 41.3 48.5 46.6 85.4 47.5c
 1950–1959 41.3 25.7 N/A 100 58.7 12.0 52.9 14.6 52.5c
Race/ethnicity/region
 Caucasian- Australian 40.8 78.8 N/A N/A N/A N/A N/A 82.3 N/A
 Caucasian- European 40.1 16.9 100 98.2 N/A 87.7 N/A 12.5 N/A
 Caucasian- American 6.3 0.7 N/A N/A 48.0 N/A 85.2 N/A N/A
 Japanese 4.6 0.1 N/A N/A 10.5 N/A N/A N/A 100
 Other Asian 2.3 2.1 N/A 0.6 9.5 N/A 7.9 1.0 N/A
 African American/Black/Caribbean 3.0 N/A N/A 0.4 25.9 N/A 5.8 N/A N/A
 Other 2.9 1.5 N/A 0.8 6.1 12.3 1.1 4.2 N/A
Education level
 ≤10 years 46.0 48.1 67.8 62.2 5.6 54.2 0 51.7 9.4
 11–12 years 17.4 17.1 25.8 10.3 15.8 16.2 13.8 15.6 59.4
 >12 years 36.6 34.9 6.4 27.5 78.6 29.6 86.2 32.7 31.2
Menopausal status
 Unknown due to surgery 19.8 25.6 17.9 16.9 4.5 15.9 3.2 28.4 11.0
 Unknown due to hormone use 14.2 16.1 21.6 13.1 11.3 12.0 25.9 7.6 2.3
 Premenopause 19.4 23.0 19.8 18.8 6.7 22.1 26.5 3.4 19.8
 Perimenopause 27.4 24.2 24.5 30.1 56.2 18.3 30.7 11.6 11.3
 Natural postmenopause 19.1 11.0 16.2 21.0 21.2 31.8 13.8 49.1 55.6
Current use of menopausal hormone therapy
 No 80.9 76.6 79.7 90.4 80.6 84.9 78.3 65.1 96.8
 Yes 19.1 23.4 20.3 9.6 19.4 15.1 21.7 34.9 3.2
Body mass index
 Normal weight (<25 kg/m2)a 48.5 48.2 63.2 44.5 36.5 52.7 50.8 42.8 85.6
 Overweight (25–29.9 kg/m2) 30.4 31.6 24.3 33.0 27.6 32.2 25.4 32.4 13.2
 Obese (≥30 kg/m2) 21.0 20.2 12.5 22.5 35.9 15.1 23.8 24.7 1.2
Smoking status
 Never smoker 54.9 56.2 34.2 48.8 59.4 52.2 50.8 62.9 86.7
 Former smoker 27.6 26.7 40.5 29.3 26.5 30.9 39.2 27.6 4.0
 Current smoker 17.4 17.1 25.3 21.9 14.1 16.9 10.1 9.5 9.3
Frequency/severity of hot flushes
 Never 47.2 44.8 47.8 35.5 56.0 63.4 67.7 56.1 54.9
 Rarely/mild 17.1 15.7 21.3 8.6 26.4 17.8 16.9 28.8 33.0
 Sometimes/moderate 22.3 24.9 20.3 36.5 7.0 10.6 9.0 11.1 7.8
 Often/severe 13.5 14.6 10.5 19.4 10.6 8.2 6.3 4.0 4.3
Frequency/severity of night sweats
 Never 57.2 54.9 57.6 48.3 63.4 68.7 77.8 62.1 75.2
 Rarely/mild 15.0 14.3 18.9 6.9 24.6 15.3 13.8 25.7 20.7
 Sometimes/moderate 17.8 19.7 15.2 31.2 4.9 8.8 2.6 8.7 3.0
 Often/severe 9.9 11.1 8.3 13.7 7.1 7.2 5.8 3.5 1.1
Frequency/severity of vasomotor symptomsb
 Never 41.9 40.3 42.2 30.1 47.5 59.1 63.5 49.7 49.5
 Rarely/mild 18.4 16.5 22.4 8.4 31.6 17.7 18.5 32.7 37.4
 Sometimes/moderate 24.2 26.9 22.4 39.1 8.3 12.3 9.0 12.2 8.6
 Often/severe 15.4 16.2 13.0 22.4 12.6 10.8 9.0 5.3 4.4

Data are presented as percentage (%).

ALSWH, Australian Longitudinal Study on Women’s Health; NSHD, National Survey of Health and Development; NCDS, National Child Development Study; SWAN, Study of Women’s Health Across the Nation; WHITEHALL, Whitehall II Study; SMWHS, Seattle Midlife Women’s Health Study; HOW, Healthy Ageing of Women Study; JMWHS, Japanese Midlife Women’s Health Study.

a

Only 357 (1.7%) women were underweight (BMI<18.5 kg/m2) and thus they were categorised into the normal weight group.

b

Vasomotor symptoms were defined as having either hot flushes or night sweats.

c

JMWHS provided age by category only (≤55 and >55 years). Thus, birth year was categorised based on age categories.